Breaking Down Shanghai GenTech Co., Ltd. Financial Health: Key Insights for Investors

Shanghai GenTech Co., Ltd. presents a mixed but compelling financial picture: trailing twelve months revenue stands at CNY 5.26 billion (as of Sept 30, 2025) after CNY 5.47 billion in 2024 (a 42.63% year-over-year surge), yet Q3 2025 revenue fell 22.68% to CNY 1.28 billion; investors should note a market capitalization of CNY 8.54 billion (share price CNY 29.76 on Dec 18, 2025) alongside profitability metrics like net income CNY 267.4 million, net profit margin 5.08%, EBITDA CNY 663.71 million (EBITDA margin 7.10%) and ROE 7.28%; the balance sheet shows total debt of CNY 3.22 billion with debt/equity 0.80 and a net cash position of CNY -2.03 billion, liquidity signals include cash CNY 1.19 billion (up 59.77%), current ratio 1.34 and quick ratio 0.69, while solvency and risk flags-Altman Z‑Score 1.58 and Piotroski F‑Score 3-contrast with valuation metrics (trailing P/E 31.79, forward P/E 12.00, P/S 1.62, P/B 2.11, EV CNY 10.91 billion) and bullish forecasts of 48.7% annual earnings growth and 27.9% annual revenue growth, inviting a deeper look at operational drivers, cash flow (operating cash flow CNY 398.8 million) and exposure to product concentration for investors seeking risk-adjusted upside

Shanghai GenTech Co., Ltd. (688596.SS) - Revenue Analysis

Shanghai GenTech's recent top-line metrics show mixed momentum: strong year-over-year growth in 2024, a moderation in TTM revenue through Sept 30, 2025, and a notable Q3 2025 slowdown versus the prior-year quarter. Key numeric highlights and implications are summarized below.

• TTM revenue (as of 2025-09-30): CNY 5.26 billion (up 6.79% YoY)
• Annual revenue 2024: CNY 5.47 billion (up 42.63% vs. 2023)
• Q3 2025 revenue: CNY 1.28 billion (down 22.68% vs. Q3 2024)
• Revenue per employee: CNY 2.75 million (1,914 employees)
• Price-to-sales (P/S) ratio: 1.62
• Market capitalization: CNY 8.54 billion; Share price (2025-12-18): CNY 29.76

Implications for investors:

• The large 2024 revenue jump (+42.63%) suggests prior-year product/market gains or recognition, but TTM growth moderates to +6.79%, indicating slower recent expansion.
• Q3 2025's -22.68% decline versus Q3 2024 raises short-term demand or execution concerns that merit investigation (seasonality, one-off contracts, or margin impacts).
• P/S of 1.62 and market cap CNY 8.54B imply the market is valuing growth potential but with tempered expectations compared with the 2024 surge.
• Revenue per employee (CNY 2.75M) is a productivity indicator investors should compare to peers to assess operational efficiency.

For broader corporate context and history that may affect revenue drivers, see: Shanghai GenTech Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shanghai GenTech Co., Ltd. (688596.SS) - Profitability Metrics

• Net income (TTM): CNY 267.4 million - Net profit margin: 5.08%
• Operating margin (TTM): 5.11% - indicates operating efficiency in primary business activities
• Gross margin (TTM): 22.07% - proportion of revenue remaining after cost of goods sold
• EBITDA (TTM): CNY 663.71 million - EBITDA margin: 7.10%
• Return on equity (ROE): 7.28% - effectiveness in generating profit from shareholders' equity
• Earnings per share (EPS): CNY 0.94 - Trailing P/E: 31.79

Shanghai GenTech Co., Ltd. (688596.SS) - Debt vs. Equity Structure

• Leverage context: 0.80 D/E positions the company below aggressive-leverage peers but above very conservative peers, indicating balanced growth funded partially by debt.
• Liquidity nuance: current ratio >1 indicates short-term solvency, while quick ratio <1 flags dependency on inventory turnover to meet immediate obligations.
• Coverage risk: interest coverage of 3.61 provides a buffer, yet leaves limited headroom against earnings volatility or rate increases.
• Equity cushion: CNY 4.04 billion book equity and CNY 12.90 book value per share create a tangible capital buffer for creditors and investors.

Shanghai GenTech Co., Ltd. (688596.SS) - Liquidity and Solvency

This section examines Shanghai GenTech's short-term liquidity, working capital position, and solvency indicators to help investors assess near-term financial flexibility and bankruptcy risk.

• Cash and cash equivalents: CNY 1.19 billion (cash growth +59.77% YoY)
• Accounts receivable: CNY 2.34 billion (+11.5% YoY)
• Working capital: CNY 1.83 billion
• Net cash per share: CNY -7.09 (negative)
• Altman Z-Score: 1.58 (elevated bankruptcy risk)
• Piotroski F-Score: 3 (signals potential financial weaknesses)

Key practical implications for investors:

• Liquidity improvement: Strong YoY cash growth (+59.77%) increases short-term flexibility, but cash of CNY 1.19 billion must be seen against payable maturities and receivables collection timing.
• Receivables & working capital: Accounts receivable of CNY 2.34 billion (+11.5%) and working capital of CNY 1.83 billion suggest operations generate current assets but may indicate slower collections or higher sales on credit.
• Per-share cash deficit: Net cash per share of CNY -7.09 highlights leverage or fund use that leaves shareholders with negative net cash exposure.
• Solvency warning signals: Altman Z-Score of 1.58 and Piotroski F-Score of 3 are red flags; they point to elevated bankruptcy risk and multiple financial weaknesses that warrant closer monitoring of cash flow, margins, and leverage.

For strategic context and alignment with company objectives, see: Mission Statement, Vision, & Core Values (2026) of Shanghai GenTech Co., Ltd.

Shanghai GenTech Co., Ltd. (688596.SS) - Valuation Analysis

• Market capitalization: CNY 8.54 billion
• Enterprise value (EV): CNY 10.91 billion
• Stock price: CNY 29.76 (as of 2025-12-18)

• Trailing vs. forward P/E differential: The drop from 31.79 to 12.00 implies either sizable expected EPS improvement over the next 12 months or a one-time drag on trailing EPS that is expected to reverse.
• P/B at 2.11: Investors are paying a premium for intangible value (IP, R&D, customer relationships) or superior return on equity prospects versus book assets.
• EV/EBITDA of 28.10: High relative to many industrial and tech peers - indicates the market prices a long-duration earnings stream or above-average margin expansion potential.
• EV/Revenue of 2.07: Used with revenue growth rates and margin expectations to back-solve implied future profitability - at this EV/sales investors expect meaningful EBIT/EBITDA generation ahead.

Shanghai GenTech Co., Ltd. (688596.SS) - Risk Factors

How these metrics interact:

• An Altman Z-Score of 1.58 combined with a Piotroski F-Score of 3 amplifies insolvency and operational weakness concerns.
• A debt-to-equity ratio of 0.80 increases sensitivity to revenue shocks-interest and principal servicing could become burdensome if cash flow weakens.
• Quick ratio at 0.69 indicates reliance on inventory or delayed receivables to meet obligations; working-capital management is critical.
• Negative net cash per share (CNY -7.09) limits the company's immediate liquidity options and may force external financing at unfavorable terms.

Operational concentration risks:

• Revenue dependence on a limited set of key products exposes margins and cash flow to single-product cycle swings.
• Regulatory, competitive, or supply-chain disruptions affecting core products could disproportionately reduce top-line stability.

Investor considerations and monitoring points:

• Track quarterly cash-flow statements for improvement in operating cash and reductions in negative net cash per share.
• Watch leverage trends-declining debt-to-equity or improved interest coverage would reduce bankruptcy risk implied by the Z-Score.
• Monitor product diversification efforts, new product revenue contributions, and concentration ratios in segment reporting.
• Assess management actions to improve the Piotroski F-Score components: profitability, leverage/liquidity, and operational efficiency.

For company context on strategy and stated priorities, see: Mission Statement, Vision, & Core Values (2026) of Shanghai GenTech Co., Ltd.

Shanghai GenTech Co., Ltd. (688596.SS) - Growth Opportunities

• Forecasted earnings growth: 48.7% CAGR (annualized).
• Forecasted revenue growth: 27.9% CAGR (annualized).
• Return on equity expected to reach 20.3% within three years.
• FY2024 net income: CNY 527.75 million.
• Operating cash flow (latest): CNY 398.8 million, supporting operations and capex.
• Dividend yield: 0.94% with a payout ratio of 42.81%.

• Domestic demand replacement for imported semiconductor and display equipment - policy-backed tailwinds.
• High-margin product mix enabled by proprietary process technology and scale gains.
• Reinvestment capacity from robust operating cash flow to accelerate R&D and production expansion.

• Growth versus valuation: accelerated earnings and revenue CAGRs must be weighed against current market pricing and execution risk.
• Balance-sheet support: near-term operating cash flow and profitable FY2024 provide a buffer for capex and working capital needs.
• Policy sensitivity: exposure to import-substitution incentives amplifies upside but can concentrate demand risk by segment.